Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fludarabine + busulfan + Thymoglobulin
- Development stage
- Phase 2
- Lead developer
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Modality
- Small Molecules, Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A reduced-intensity conditioning (RIC) regimen consisting of the purine analog fludarabine, the alkylating agent busulfan, and the T-cell depleting polyclonal antibody Thymoglobulin (anti-thymocyte globulin). Developed by the University Hospital, Clermont-Ferrand, this combination is used as a preparatory therapy for pediatric patients with refractory hematologic neoplasms or solid tumors undergoing allogeneic hematopoietic stem cell transplantation (HSCT). The regimen is designed to facilitate donor cell engraftment through immunosuppression and myelosuppression while reducing the high toxicity profile associated with standard myeloablative conditioning protocols.
- Brand names
- Thymoglobuline
- Other names
- fludarabine + busulfan + anti-thymocyte globulinFlu-Bu-ATGFludarabine-Busulfan-ALSRICE regimen
02
Targets
DNACD2 (T-cell Surface Antigen CD2)CD3 (T-cell surface glycoprotein CD3)CD4 (T lymphocyte surface antigen)CD8A (CD8 alpha/beta Coreceptor)
Beyond the preview
Go deeper on fludarabine + busulfan + Thymoglobulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fludarabine + busulfan + Thymoglobulin.